Continuous Glucose Monitoring Devices Market, By Component (Sensors, Transmitters, and Receivers), By End User (Hospitals, Home care, and Others), By Region (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)
Continuous Glucose Monitoring Devices Market is estimated to be valued at USD 7.81 Bn in 2025 and is expected to reach USD 15.12 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.9% from 2025 to 2032.
Report Coverage
Report Details
Base Year:
2024
Market Size in 2025:
USD 7.81 Bn
Historical Data for:
2020 To 2024
Forecast Period:
2025 To 2032
Forecast Period 2025 to 2032 CAGR:
9.90%
2032 Value Projection:
USD 15.12 Bn
Continuous glucose monitor (CGM) is a medical device used by people with diabetes to monitor blood sugar (glucose) on a continual basis, e.g. people with type I, type II diabetes, or other types of diabetes (e.g. gestational diabetes). Thus, with the increasing prevalence of diabetes across the globe, the demand for CGM devices is also increasing rapidly, worldwide.
Market Dynamics
Increasing prevalence of diabetes, growing geriatric population, increasing demand for continuous glucose monitors (CGM), increasing adoption of technologically advanced devices, and increasing awareness among people across the globe are major factors expected to augment the growth of thelobal continuous glucose monitoring devices market.
For instance, in May 2023, Health tech company, January AI, introduced a new generative artificial intelligence (AI)-enabled app to estimate and predict the glucose response of individuals to more than 32 Bn food items. The tool requires users to wear a CGM only once and it can function even if members are not using a CGM. The platform is designed to provide users with information such as glucose estimates, predictions and key insights on an ongoing basis. Users also receive insights on increasing fibre consumption, calorie recommendations, intermittent fasting, lowering glucose-spiking foods, and getting post-meal walks.
Key features of the study
This report provides in-depth analysis of the global continuous glucose monitoring devices market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global continuous glucose monitoring devices market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Medtronic, Dexcom, Inc., Abbott, Novo Nordisk A/S, Ypsomed, GlySens Incorporated, and F. Hoffmann-La Roche Ltd., among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global continuous glucose monitoring devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global continuous glucose monitoring device market.
Market Segmentation
Global Continuous Glucose Monitoring Devices Market, By Component
Sensors
Transmitters
Receivers
Global Continuous Glucose Monitoring Devices Market, By End User
Hospitals
Home care
Others
Global Continuous Glucose Monitoring Devices Market, By Geography
North America
U.S.
Canada
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC Countries
Israel
Rest of Middle East
Africa
South Africa
North Africa
Central Africa
Company Profiles
Medtronic
Dexcom, Inc.
Abbott
Novo Nordisk A/S
Ypsomed
GlySens Incorporated
Hoffmann-La Roche Ltd.
Table of Contents
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Component
Market Snapshot, By End User
Market Snapshot, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Increasing prevalence of diabetes around the world